TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03867669

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Open Bay Unit
Description: The eligible infants will be randomized at birth/admission to either the single patient room (experimental) or the open bay unit (Comparator)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single patient room
Description: The eligible infants will be randomized at birth/admission to either the single patient room (experimental) or the open bay unit (Comparator)
Study: NCT02160379

Intervention type: OTHER
Intervention: standard test meal

Intervention type: OTHER
Intervention: standard test meal

Intervention type: OTHER
Intervention: standard test meal
Study: NCT03810690

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-3704
Description: mRNA-3704 dispersion for intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-3704
Description: mRNA-3704 dispersion for intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-3704
Description: mRNA-3704 dispersion for intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-3704
Description: mRNA-3704 dispersion for intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-3704
Description: mRNA-3704 dispersion for intravenous (IV) infusion
Study: NCT03609658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Navigator Pathway
Description: In the Nurse Navigator Pathway, nurse navigators are being used as leverage to: approach qualified patients to initiate advance care planning discussions, schedule advance care planning visit with patients' primary care provider to further discuss advance care planning and to mail advance care planning resources to patients after their initial advance care planning discussion.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: In the Usual Care arm, there is no approach by nurse navigators to initiate advance care planning discussions and it does not have a structure advance care planning visit. Therefore, no further action is required for the patients who were randomly assigned to the usual care arm.
Study: NCT03879148

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Erector spinae plane block was performed to the patients under aseptic conditions
Study: NCT02594215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7075 (miransertib)
Description: MK-7075 or miransertib (formerly ARQ 092) is small molecule that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a phase I study to determine a recommended dose for subsequent trials, which will determine the efficacy of miransertib in Proteus syndrome.
Study: NCT01365403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: Single oral dose, Day 1 of study period 1 and Day 16 of study period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbamazepine
Description: multiple oral doses, Days 1-24 of study period 2
Study: NCT02306564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: given to patients at high risk for OHSS
Study: NCT01282437

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation
Description: * 18 fractions of 2Gy~* 12 fractions of 2.5Gy~* 10 fractions of 3 Gy
Study: NCT00269399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin (Xifaxan)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study: NCT06750029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical clown visits
Description: The intervention is 15-minute visits from MCs twice daily during the first two days of admission. The clowns use various techniques to relax the patients (e.g. music, singing, playing, humor, guided imagination) and helpe encourage children to begin drinking and eating on their own.
Study: NCT03467724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Radiofrequency (FRF)
Description: Fractional radiofrequency will be delivered to the area of the surgical scar.
Study: NCT01325870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACD-CPR

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITPR
Description: standard CPR with use of the CirQlator intrathoracic pressure regulator (ITPR)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: S-CPR
Description: standard manual CPR

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impedance Threshold Device (ITD)
Study: NCT04547348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab Injection
Description: Injections made subcutaneously per standard description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Denosumab Injection
Description: Injections made subcutaneously per standard description
Study: NCT02577523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND0612 (Levodopa/Carbidopa solution)
Description: The total daily dose of levodopa/carbidopa 720/90 mg. Device: CRONO TWIN pump system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD
Description: The total daily dose levodopa/carbidopa from ND0612 538/67 mg. Morning dose of oral IR-LD/CD 150/15 mg. Device: CRONO TWIN pump system.
Study: NCT00697814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Description: Clomiphene 50 mg/day for 12 weeks
Study: NCT05386446

Intervention type: DRUG
Intervention: Interferon gamma human recombinant (IFN-G)
Description: nasal form
Study: NCT00943605

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel and Traditional Electrosurgery
Description: The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade
Description: The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
Study: NCT00531518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine
Description: Oral, daily, generally at lower than manufacturer's recommendations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational multifamily group treatment
Description: Families and patients are educated on psychobiology of psychosis and trained in coping skills to avoid psychosis by reducing stress and optimizing social environment at home, school, work

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported employment and education
Description: Participants are provided direct assistance, guidance and ongoing support to gain employment and succeed in their educational goals.
Study: NCT00730002

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Angiography (MRA)
Description: As part of the Magnetic Resonance(MR) scan, you will need to lie still on a padded MR table inside the MR machine for about 15 minutes at a time while MR studies are being performed on you. The total time for the clinical portion of the MR study is approximately 35-40 minutes and there will be an additional 30 minutes for the research related MR studies. The total time you will spend on the MR table for this research will seldom be more than one hour.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic resonance imaging
Description: MR spectroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic resonance imaging
Description: MR spectroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRA
Description: MRA of the brain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRA
Study: NCT03164837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-RM26
Description: Single-dose 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans.
Study: NCT01961687

Intervention type: DEVICE
Group type: OTHER
Intervention: Resorbable Mesh
Description: Phasix Mesh
Study: NCT02278458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icotinib
Description: Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
Study: NCT04673708

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: H - Test
Description: Showing different videos for a sexual stimulus and monitor the vitals of each participants to measure any changes can occur with each video.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: H - Test
Description: Showing different videos for a sexual stimulus and monitor the vitals of each participants to measure any changes can occur with each video.
Study: NCT01337726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Psychotherapy and Illness Management
Description: Participants will have 10 weekly visits with a study clinician at their home and by phone. They will focus on their self care and illness management as well as how to manage their mood/cope emotionally. Follow up assessments will occur at 26 and 52 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Illness Management Only
Description: Participants in this group will have 10 weekly sessions with a study clinician at home and by phone. They will focus only on how they manage their illness. Follow up assessments will occur at 26 and 52 weeks.
Study: NCT02387567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Paraspinal block with 3ml lidocaine injection at 1%.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Lidocaine
Description: Sham injection, without lidocaine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Standard treatment only, without lidocaine or sham injection.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment only, without lidocaine or sham injection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment only, without lidocaine or sham injection.
Study: NCT01604369

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medtronic Freezor Max Cardiac Cryoablation Catheter
Description: Cryoablation is performed using a sequential application technique point-by-point from the tricuspid annulus to the inferior vena cava. Ablation is performed at a target temperature of -80 ºC. Each application will last for 240 seconds.
Study: NCT04272489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG-Pattern Recognition Controller
Description: Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device in a home trial.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMG-Pattern Recognition Controller
Description: Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device in a home trial.
Study: NCT04299217

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zynamite®
Description: Zynamite® is a novel mango (Mangifera indica) leaf extract standardized to contain 60% of the polyphenol mangiferin. Zynamite® is classified as a food or food supplement and is available for purchase within the EU. Zynamite® is not associated with any significant deleterious side effects.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator (carrier)
Study: NCT01405469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peroral Endoscopic Myotomy
Description: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. An electric generator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips
Study: NCT02951936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NiCAS treated
Description: Measure each patient with the NiCAS once a day If Cardiac Index \< 2.9 +Total Peripheral resistance Index \>3000+Mean arterial pressure \>70mmHG then add vasodilators.~If Heart Rate\<60 consider to reduce beta blockers dose If Cardiac Index\>4.2 and Mean arterial pressure 70-100mmHG and HR \>100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non NiCAS treated
Description: Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment For treatment we will use the standard care
Study: NCT04751045

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS liver biopsy
Description: Endoscopic ultrasound guided liver biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS liver biopsy
Description: Endoscopic ultrasound guided liver biopsy
Study: NCT00730002

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diffusion Imaging
Description: MRA of the Brain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perfusion imaging.
Description: MRA of the brain
Study: NCT02033096

Intervention type: DRUG
Intervention: Stannsoporfin
Description: No intervention was administered during this observational study

Intervention type: DRUG
Intervention: Stannsoporfin
Description: No intervention was administered during this observational study

Intervention type: DRUG
Intervention: Stannsoporfin
Description: No intervention was administered during this observational study

Intervention type: DRUG
Intervention: Placebo Control
Description: No intervention was administered during this observational study

Intervention type: OTHER
Intervention: Phototherapy (as needed)
Description: No intervention was administered during this observational study

Intervention type: OTHER
Intervention: Phototherapy (as needed)
Description: No intervention was administered during this observational study

Intervention type: OTHER
Intervention: Phototherapy (as needed)
Description: No intervention was administered during this observational study

Intervention type: OTHER
Intervention: Phototherapy (as needed)
Description: No intervention was administered during this observational study
Study: NCT02225106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Subjects will be treated with oral methylphenidate, using a forced titration up to a dose of 30 mg given twice daily for 4 weeks. At that point, the neuropsychologic tests are repeated.
Study: NCT01767727

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Soft tissue coverage
Description: The dorsal homodigital island flaps are used for soft tissue coverage of multiple finger defects
Study: NCT04034355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calmangafodipir (5 µmol/kg)
Description: PledOx will be given to patients as an i.v. infusion, on top of mFOLFOX6 chemotherapy. PledOx is a solution in 20 mL single dose glass vials.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via the same route as PledOx (i.v. infusion). Placebo is a solution in 20 mL single dose glass vials.
Study: NCT01956708

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: RIPC
Description: 3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIPC
Description: 3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
Study: NCT02914769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ayahuasca
Description: patients will receive a single dose of ayahuasca.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will receive a single dose of a passive placebo.
Study: NCT01709812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individualized patient support program
Description: individualized patient support with compliance supporting tools

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Study: NCT04154358

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV testing
Description: will perform HPV testing with self-collected specimen
Study: NCT04458961

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-stage
Description: A one-stage revision operation involves one operation to remove the joint, thoroughly cleaning the infected area and then implanting a new joint immediately.
Study: NCT04142788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: Patiromer (8.4g/day to 25.2g/day) and spironolactone (up to 200mg/day) or eplerenone (up to 50mg/day if spironolactone not acceptable). Treatments should be titrated to maintain serum potassium close to the target of 4.5mmol/L.
Study: NCT01225939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8329
Description: tablet
Study: NCT04458961

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-stage
Description: A two-stage revision operation involves two operations: the joint is removed in one operation, a temporary spacer device is inserted, then the infection is treated with antibiotics, and then a new joint is implanted in a second operation.
Study: NCT02061176

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal Haemorrhoidal Dearterialization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Haemorrhoidectomy
Study: NCT00270387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natrecor (nesiritide)
Study: NCT01365455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg
Description: secukinumab (AIN457) 150mg or 300mg subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg
Description: secukinumab (AIN457) 150mg or 300mg subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg
Description: secukinumab (AIN457) 150mg or 300mg subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg
Description: secukinumab (AIN457) 150mg or 300mg subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to secukinumab 150 mg
Description: Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to secukinumab 150 mg
Description: Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to secukinumab 150 mg
Description: Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to secukinumab 150 mg
Description: Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to secukinumab 150 mg
Description: Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous
Study: NCT01920243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Mechanics Program
Description: The intervention will consist of six modules that will address attitudes, self-monitoring, communication and organizational skills, problem solving skills and stress management as presented through the Health Mechanics program. These modules are designed to take place over 6 phone calls of approximately 45 minutes each. In order to provide flexibility for the participants, the quantity and duration of calls may vary depending on the extent that the participant completes the homework and the amount of time they need to learn the skill.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Mechanics Program
Description: The intervention will consist of six modules that will address attitudes, self-monitoring, communication and organizational skills, problem solving skills and stress management as presented through the Health Mechanics program. These modules are designed to take place over 6 phone calls of approximately 45 minutes each. In order to provide flexibility for the participants, the quantity and duration of calls may vary depending on the extent that the participant completes the homework and the amount of time they need to learn the skill.
Study: NCT00916448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: capsules of 150 mg, 2 capsules, twice daily on 4 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E. coli endotoxin
Description: 2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E. coli endotoxin
Description: 2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
Study: NCT03117946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples
Description: blood and tumor tissue sample
Study: NCT02843191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: 5-FU, Leucovorin, and Oxaliplatin (FOLFOX regimen)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 5-FU, Leucovorin, and Oxaliplatin (FOLFOX regimen)